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There are 26 approved antiretroviral drugs available in
2012 in 6 mechanistic classes: reverse transcripatase inhi-
bitors (both nucleosides and non-nucleosides), protease
inhibitors, entry inhibitors (both fusion inhibitors and
CCR5 receptor antagonists), and integrase inhibitors. Cur-
rent antiretroviral therapy combinations dramatically
decrease HIV-related morbidity and mortality. However,
despite these advances, some current antiretroviral regi-
mens may be inconvenient, toxic, and/or have suboptimal
antiretroviral activity, particularly against drug-resistant
viruses. Thus, newer compounds are needed that improve
convenience and tolerability, reduce toxicity, and improve
antiretroviral activity, particularly against drug-resistant
viruses. Additionally, new drugs may better penetrate tis-
sue reservoirs (e.g. genital tract, central nervous system),
exploit new targets with new mechanisms of action, or be
administered in new formulations.
There are a number of HIV investigational drugs in
development currently. These include a new pharmacoki-
netic “boosting” agent, cobicistat (GS-9350) and newer
antiretroviral agents in a number of classes, including new
nucleoside reverse transcriptase inhibitors, non-nucleoside
reverse transcriptase inhibitors, protease inhibitors, entry
inhibitors, and integrase inhibitors. Of those in the pipe-
line, a few compounds are in advanced stages of develop-
ment: the nucleoside analogue GS-7340, a pro-drug of
tenofovir (phase 2); and the integrase inhibitors, elvitegra-
vir (phase 3 completed) and dolutegravir (phase 3). In
addition, there are drugs with new mechanisms of action
in development, including the CD4 attachment inhibitor,
BMS-663068 (phase 2), and the CCR5 antagonist, cenicri-
viroc (phase 2).
Probably the greatest need in the HIV clinic today is
compounds that have activity against multidrug-resistant
viral strains. Another important need is alternative one-
pill, once-daily formulations for both initial and subse-
quent regimens. However, the clinical use of these newer
agents will depend on the results of phase 3 clinical trials,
and the timeline for development and availability.
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